US 11,738,028 B2
Therapeutic regimen
Jay Prakash Jain, Pleasanton, CA (US); Franz Joel Leong, Singapore (SG); Cornelis Winnips, Flueh (CH); and Marie-Christine Wolf, St. Louis (FR)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Jul. 29, 2021, as Appl. No. 17/388,277.
Application 17/388,277 is a continuation of application No. 16/669,275, filed on Oct. 30, 2019, abandoned.
Application 16/669,275 is a continuation of application No. 15/961,394, filed on Apr. 24, 2018, abandoned.
Claims priority of application No. 201711014459 (IN), filed on Apr. 24, 2017.
Prior Publication US 2022/0088022 A1, Mar. 24, 2022
Int. Cl. A61K 31/522 (2006.01); A61K 31/137 (2006.01); A61P 33/06 (2006.01); A61K 31/4985 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/522 (2013.01) [A61K 31/137 (2013.01); A61K 31/4985 (2013.01); A61K 45/06 (2013.01); A61P 33/06 (2018.01); A61K 2300/00 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A pharmaceutical combination comprising about 400 mg to about 1000 mg lumefantrine formulated as a solid dispersion and about 200 mg to about 1000 mg of 2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone, or a pharmaceutically acceptable salt thereof.